Pustulosis palmaris et plantaris (PPP) and pustulotic arthro-osteitis (PAO) are tonsil-related diseases. Treatment outcome of tonsillectomy and prognostic factors influencing the outcome have not been analyzed quantitatively. We evaluated those using the Palmoplantar Pustulosis Area and Severity Index (PPPASI). At 1, 3, 6, 12, 24 and more than 24 months post-tonsillectomy, 20 (31%), 34 (48%), 70 (60%), 57 (80%), 36 (95%) and 23 (96%) patients realized 80% or more improvement of PPP skin lesions, respectively, and eight (17%), 23 (36%), 30 (50%), 38 (79%), 12 (100%) and four (100%) patients showed 80% or more improvement of PPPASI (i.e. PPPASI% ≥ 80%), respectively. At 1, 3, 6, 12 and more than 12 months post-tonsillectomy, 19 (73%), 21 (66%), 27 (73%), 19 (79%) and 15 (83%) patients realized a disappearance of PAO-induced arthralgia, respectively. Kaplan-Meier analysis of 80 patients with PPP revealed that, at 12 and 24 months post-tonsillectomy, lesions disappeared (i.e. PPPASI = 0) in 38% and 66% of patients, respectively, and lesions improved by 80% or more (i.e. PPPASI% ≥ 80%) in 71% and 95% of patients, respectively. The log-rank test and univariate and multivariate analyses showed that smoking cessation post-tonsillectomy and PAO were significant predictive factors for the early disappearance of skin lesions. This report is the first demonstrating objective evidence of the great efficacy of tonsillectomy to improve PPP skin lesions. Even post-tonsillectomy, smoking inhibited the early disappearance of the lesions.
INTRODUCTION
Palmoplantar pustulosis (PPP) is characterized by symmetrical, erythematous, scaly plaques with numerous, sterile, non-bacterial, pinpoint pustules that are restricted to the palms and soles. Palmoplantar pustulosis is often classified as a localized form of pustular psoriasis; 1 however, the definition or pathogenesis of PPP and pustular psoriasis is still subject to argument. Palmoplantar pustulosis occurs in approximately 0.05% of the population and occurs more frequently in women aged 30-60 years. 2 Exacerbation of PPP occurs after upper respiratory infections, particularly acute tonsillitis; 3, 4 therefore, it may be a typical tonsil-related disease. With regard to the clinical outcome of tonsillectomy to treat skin lesions of patients with PPP, Andrews et al. 3 first reported that nine of 24 Caucasian patients with PPP were entirely cured of PPP after tonsillectomy. After the Andrews et al.
study, research demonstrating the effectiveness of tonsillectomy for PPP has primarily come from Japan. In 1977, Ono et al. 5 reported that 73 tonsillectomized patients had significantly better improvement than 83 patients who received other treatment methods (84% vs 39%, P < 0.01). In another study, Ono et al. 6 uninterruptedly reported that, among 124 patients more marked improvement of PPP skin lesion after tonsillectomy. We previously conducted a prospective case series of 116 patients with PPP who underwent tonsillectomy, and found that 94% (109/116) of patients reported that their skin lesions improved after tonsillectomy. 8 These results suggest that tonsillectomy is very effective in alleviating PPP skin lesions. However, nearly all reports employed subjective evaluations of PPP skin lesions, based on patients' self-assessment. Bhushan et al. 9 proposed using the Palmoplantar Pustulosis Area and Severity Index (PPPASI) as an objective evaluation method for quantifying PPP skin lesions. This method makes it possible to objectively evaluate the skin condition of patients with PPP after tonsillectomy. Sternocostoclavicular hyperostosis (SCCH) is hyperostosis that primarily affects the intra-sternocostoclavicular joints, and induces painful swelling of the affected joints. 10 It frequently accompanies PPP, a combination that is called pustulotic arthro-osteitis (PAO). 11 Moreover, the combination of PPP and PAO has been proposed as a syndromic disorder comprising synovitis, acne, PPP, hyperostosis and osteitis. 12 In other studies, 13, 14 Kataura et al. reported that 52% (46/89) of patients with SCCH or PAO experienced disappearance of or a remarkable improvement in joint pain for longer than 3 months during the observation period. Therefore, like PPP, PAO is also considered a typical tonsil-related disease. 4 The treatment outcome and prognostic factors of the tonsilrelated diseases PPP have not been analyzed quantitatively. Therefore, in the current study, we evaluated skin lesions in patients with PPP before and after tonsillectomy by using a conventional subjective method (i.e. patient self-assessment) and by using an objective measure, the PPPASI. Moreover, we performed Kaplan-Meier analysis using PPPASI values, and attempted to determine predictive factors for the improvements in skin lesions, based on the log-rank test and univariate and multivariate analyses.
METHODS

Patients' characteristics
One hundred thirty-eight patients with PPP, who underwent tonsillectomy in the Department of Otolaryngology-Head and Neck Surgery at Asahikawa Medical University (Asahikawa, Japan) during 1998-2016, were enrolled in this study. All patients were diagnosed as having PPP and referred to our department by dermatologists, who wanted the patients to undergo tonsillectomy because the PPP skin lesions were refractory to conservative treatment. Clinical information was obtained retrospectively from hospital charts or by direct interview. Table 1 lists the clinical characteristics in each study: age, sex, period of having the disease before treatment, presence of PAO, deterioration of PPP skin lesion with the upper respiratory infection, smoking status, tonsillar hypertrophy (i.e. modified Mackenzie classification of ≥II), high serum antistreptolysin O (ASO) level, transient deterioration of the skin lesion after tonsillectomy, quitting smoking within 1 month after tonsillectomy and the observation period after tonsillectomy. The diagnosis of PAO is based on painful swelling in the sternoclavicular region where bone scintigraphy shows typical uptake. 11 Modified Mackenzie classification was subjected to Selma et al.'s report. 15 Briefly, tonsils inside the tonsillar fossa lateral posterior pillars were classified as grade I, and tonsils outside the pillars were classified as grade II or more. This study was approved by the medical ethics committee of Asahikawa Medical University of Medical Science (approval no. 224-5). We obtained written informed consents from all participants in this study.
Patients' self-assessment of PPP skin lesions after tonsillectomy
The Skin Severity Score (SSS) was used to evaluate the severity of palmar and plantar lesions in each patient, as described previously. 4, 16 In brief, the 138 patients subjectively evaluated their skin conditions after tonsillectomy on SSS value of 1-10; the condition before tonsillectomy was defined as SSS 10. If the patients realized that PPP skin lesions had completely Patients' self-assessment of PAO-induced arthralgia after tonsillectomy
The Pain Severity Score (PSS) was used to evaluate the severity of arthralgia caused by PAO. Fifty patients with PAO subjectively evaluated their pain after tonsillectomy on a scale of 1-10; the PSS for pain before tonsillectomy was defined as PSS 10. If the patients realized that their pain had completely disappeared after tonsillectomy, they were expected to answer that PSS was 0.
PPPASI scoring of PPP skin lesions before and after tonsillectomy
Skin lesions in 80 of the 138 patients were evaluated by PPPASI scoring proposed by Bhushan et al. 9 This index is used widely to assess the severity of chronic plaque psoriasis. 17 In brief, erythema (E), pustules (P) and desquamation (D)
were evaluated on a scale of 0-4, whereas the area was evaluated on a scale of 0-6. The following formula was used for quantification: score = (E + P + D) 9 area 9 0.2 (right palm)
The PPPASI can vary from 0 (i.e. absence of disease) to 72 (i.e. most severe palmoplantar psoriasis possible). In addition, the improvement rate of PPPASI (PPPASI%) was calculated by dividing the decrement in the PPPASI through tonsillectomy by the PPPASI value before tonsillectomy.
Kaplan-Meier analysis in the improvement of PPP skin lesions and PAO arthralgia Kaplan-Meier analyses were used for the time-to-event analyses. The primary end-point was the disappearance of a skin lesion (i.e. PPPASI = 0 or SSS = 0) or the disappearance of arthralgia (PSS = 0). The secondary end-point was an improvement of 80% or more in the lesion (i.e. PPPASI% ≥ 80%, SSS ≤ 2 or PSS ≤ 2). Patients whose skin lesions or arthralgia worsened after initially disappearing or improving 80% or more were considered as censored cases.
Treatment outcome, based on variable clinical factors associated with an improvement in PPP skin lesions Eighty patients with PPP who were scored by using the PPPASI were divided into two groups, based on each clinical factor as follows: patients' age (≥53 or <53 years; median age, 53 years), sex, presence or absence of comorbid PAO, period of having the disease before treatment (≥2 or <2 years; median period, 2 years), deterioration in the skin lesion with an the upper respiratory infection (yes or no), smoker (yes or no), tonsillar hypertrophy level (modified Mackenzie classification I or ≥II), serum level of ASO (high or normal), PPPASI value before tonsillectomy (≥7.8 or <7.8; median value, 7.8), transient deterioration in the PPP skin lesion after tonsillectomy (presence or absence) or smoking cessation after tonsillectomy within 1 month after tonsillectomy (yes or no).
The two groups were compared by using log-rank test and univariate analysis. Moreover, the clinical factors with P < 0.3 under univariate analysis were extracted for multivariate analysis. 
Statistics
Two-group time-dependent comparisons were tested appropriately using the Wilcoxon signed-rank test. To determine the associated factors, clinical variables selected by univariate analysis were entered into a multivariable logistic regression model. Statistical analyses were performed using JMP version 11 â software (SAS Institute, Cary, NC, USA). Statistical tests were based on a level of significance level of P < 0.05.
RESULTS
SSS after tonsillectomy
Postoperative changes in the SSS over time are shown in Figure 1 (a) and Table 2 . At 1, 3, 6, 12, 24, more than 24 months and last visit after tonsillectomy, the median and 25-75 percentile of the SSS were 4 and 2-6, 3 and 1-5, 2 and 0-4, 1 and 0-2, 0 and 0-1, 0 and 0-1, and 1 and 0-2, respectively. The SSS decreased significantly over time within 24 months after tonsillectomy. At 1, 3, 6, 12, 24, more than 24 months and last visit after tonsillectomy, PPP skin lesions disappeared (i.e. SSS = 0) in three (5%), 12 (17%), 30 (26%), 28 (44%), 21 (55%), 16 (67%) and 60 (43%) patients, respectively. In addition, 20 (31%), 34 (48%), 70 (60%), 57 (89%), 36 (94%), 23 (95%) and 106 (77%) patients had 80% or more improvement in the lesion (i.e. SSS ≤ 2) at 1, 3, 6, 12, 24, more than 24 months and last visit after tonsillectomy, respectively. Kaplan-Meier analysis revealed that, at 12 and 24 months after tonsillectomy, the PPP lesion disappeared (i.e. SSS = 0) in 38% and 66% of patients, respectively (Fig. 1b) , and improved 80% or more (i.e. SSS ≤ 2) in 71% and 95% of patients, respectively (Fig. 1c) .
SSS of palms or soles after tonsillectomy
Postoperative changes in the SSS of palms over time are shown in Figure 2 (a) and Table 3 . At 1, 3, 6, 12, 24, more than Table 3 . At 1, 3, 6, 12, 24, more than 24 months and last visit after tonsillectomy, the median and 25-75 percentile of the SSS were 4 and 1-6, 2 and 1-5, 2 and 0-4, 1 and 0-3, 0 and 0-0.5, 0 and 0-1, and 0 and 0-3, respectively. The SSS significantly decreased between before tonsillectomy and 1 month after tonsillectomy, 6 and 12 months after tonsillectomy, or 12 and 24 months after tonsillectomy.
Kaplan-Meier analysis revealed that the PPP lesions of palms and that of soles disappeared (i.e. SSS of palms or soles = 0) in 51% and 38% of patients at 12 months after tonsillectomy, respectively (Fig. 2c) , and improved 80% or more (i.e. SSS of palms or soles ≤2) in 87% and 71% of patients, respectively (Fig. 2d) . According to Kaplan-Meier curves, the rate of disappearance or 80% or more improvement in PPP lesions of palms seemed to be higher than that of soles at each time point; however, the difference was not statistically significant (disappearance, P = 0.08; ≥80% improvement, P = 0.11).
PSS after tonsillectomy
Postoperative change in the PSS is shown in Figure 3 (a) and Table 4 . At 1, 3, 6, 12, more than 12 months and last visit after tonsillectomy, the median and 25-75 percentile of the PSS were 0 and 0-3.5, 0 and 0-3.75, 0 and 0-1, 0 and 0-0, 0 and 0-0, and 0 and 0-1, respectively. The PSS was significantly decreased in each of these observation periods, compared with before tonsillectomy. At 1, 3, 6, 12, more than 12 months and last visit after tonsillectomy, PAO arthralgia disappeared Kaplan-Meier analysis revealed that, at 6 and 12 months after tonsillectomy, PAO arthralgia disappeared (i.e. PSS = 0) in 68% and 78% of patients, respectively (Fig. 3b) , and improved 80% or more (i.e. PSS ≤ 2) in 75% and 87% of the patients, respectively (Fig. 3c) .
PPPASI before and after tonsillectomy
Changes in the PPPASI before and after tonsillectomy are shown in Figure 4 (a) and Table 5 .
Changes in the PPPASI% after tonsillectomy are shown in Figure 4 (b) and and 83.6-100%, 100% and 100-100%, 100% and 100-100%, and 100% and 76-100%, respectively. The PPPASI% significantly increased over time within 24 months after tonsillectomy.
At 1, 3, 6, 12, 24, more than 24 months and last visit after tonsillectomy, the PPP skin lesion disappeared (i.e. PPPASI = 0) in three (6%), 13 (20%), 20 (33%), 26 (54%), 10 (83%), four (100%) and 42 (53%) patients, respectively. In addition, at 1, 3, 6, 12, 24, more than 24 months and last visit after tonsillectomy, the PPPASI improved 80% or more (i.e. PPPASI% ≥80%) in eight (17%), 23 (36%), 30 (50%), 38 (79%), 12 (100%), four (100%) and 57 (71%) patients, respectively. Kaplan-Meier analysis revealed that, at 12 and 24 months after tonsillectomy, 44% and 78% of patients, respectively, had 100% improvement in the PPPASI (Fig. 4c) , and that 70% and 95% of patients, respectively, had 80% or more improvement in the PPPASI (Fig. 4d) .
Clinical factors correlated with the PPPASI before tonsillectomy or the presence of PAO
Clinical factors correlated with the PPPASI before tonsillectomy or with the presence PAO are shown in Table 6 . The PPPASI value before tonsillectomy was significantly higher in patients who experienced an exacerbation in their PPP skin lesions with an upper respiratory infection, who smoked or who failed to quit smoking after tonsillectomy, compared with patients who had not experienced an exacerbation, who did not smoke or who successfully quit smoking. Moreover, the incidence of PAO in patients who had PPP for more than 3 years before tonsillectomy was significantly higher, compared with its incidence in patients with PPP for less than 3 years.
Correlation between SSS, PSS and PPPASI%
The correlation between SSS, PSS and PPPASI% are shown in Figure 5 . After tonsillectomy, there was significant negative correlation between the SSS and PPPASI% at 1, 3, 6 (Fig. 5a ), and at 12 months and the last visit (Fig. 5b) . However, there was no significant correlation between the PSS and PPPASI%, or between the PSS and the SSS at any observation period, including last visit after tonsillectomy (Fig. 5c,d ).
Clinical factors contributing to the improvement in the PPP skin lesion after tonsillectomy
The results of log-rank tests are summarized in Table 7 . Successfully quitting smoking after tonsillectomy and a PPPASI value of less than 7.8 were the clinical factors that significantly predicted the disappearance of PPP skin lesions (i.e. PPPASI = 0). Moreover, the presence of PAO was a factor that significantly predicted an 80% or more improvement in the PPP skin lesion (i.e. PPPASI%-≥ 80%).
The results of univariate and multivariate analysis, based on Cox proportional-hazards model, are summarized in Table 8 . Univariate analysis also revealed that quitting smoking, a PPPASI value 7.8 or more and the presence of PAO were significant predictive factors impacting the postoperative course of PPP skin lesion. Moreover, multivariate analysis revealed that quitting smoking was an independent predictor for the disappearance of PPP skin lesion, and the presence of PAO was a predictor for the disappearance of and a more than 80% improvement in a PPP skin lesion. 
DISCUSSION
In this study, approximately 90% of patients with PPP experienced an improvement of their skin lesion at 12 months after tonsillectomy, based on objective and subjective evaluation methods. This report is the first demonstrating objective evidence of the great efficacy of tonsillectomy for improving PPP skin lesions, as analyzed using the PPPASI. With some conservative treatments such as local steroid and psoralen and ultraviolet A, research also shows that more than 60% of patients have an improvement in their skin; however, a relapse cannot be avoided after stopping the treatment and a complete cure cannot be achieved. 7 With regard to a change in PPP skin lesion after tonsillectomy over time, Kaplan-Meier analysis in the current study revealed that the PPP skin lesion disappeared at 12 and 24 months after tonsillectomy in 44% and 87% of patients, respectively. Ono et al. 6 have also reported that 59% and 72% of the patients were cured at the same time points, based on Kaplan-Meier analysis. Therefore, to determine the efficacy of tonsillectomy for PPP skin lesions, clinicians should follow patients at least 24 months after tonsillectomy. Kataura et al. 13, 14 reported that 90 (31%) of 289 tonsillectomized patients with PPP also had PAO, and that arthralgia caused by PAO disappeared in 46 (52%) patients for longer than 3 months during the observation period. In this study, we similarly found that 50 (36%) of 138 tonsillectomized patients with PPP had PAO, and the arthralgia had disappeared 3 months after tonsillectomy in 21 (66%) of 32 patients. No report exists concerning clinical factors in patients with PPP that has demonstrated its strong association with PAO. This study is the first showing a positive correlation between the period from the onset of PPP to tonsillectomy and the presence of PAO. This result suggests that early treatment intervention for patients with PPP may prevent the development of PAO. Kaplan-Meier analysis revealed that, at 6 and 12 months after tonsillectomy, 68% and 78% of patients, respectively, showed the disappearance of PAO arthralgia. The percentage reached a plateau at 12 months after tonsillectomy. Therefore, to determine the efficacy of tonsillectomy for PAO arthralgia, 12 months are sufficient to follow up patients after tonsillectomy. This effect was seen earlier than that of the PPP skin lesions after tonsillectomy. A reason may be that the evaluation indicator of PAO was arthritic pain. If we used uptake of bone scintigraphy in the sternoclavicular region as an evaluation indicator, the results might be different. In fact, we experienced a patient with PAO who underwent a routine bone scintigraphy after tonsillectomy. Only 10 years after tonsillectomy was uptake of the region decreased. We found two independent clinical factors that predicted a favorable outcome for PPP skin lesions after tonsillectomy: presence of PAO and quitting smoking after tonsillectomy. Tonsil-related factor such as tonsillar hypertrophy and deterioration of PPP skin lesions with upper respiratory infection were not significantly related to disappearance or improvement of PPP skin lesions after tonsillectomy. We cannot resolve why the presence of PAO indicates a favorable outcome for PPP skin lesions. Based on our basic research, we speculate that a number of activated tonsillar T cells, 16 which express several receptors such as cutaneous lymphocyte-associated antigen, 18 chemokine receptor 6 19 and b1-integrin, 20 is increased by a hyper-immune response against a-streptococci (i.e. tonsil indigenous bacteria). These tonsillar T cells migrate into PPP skin lesions, which express their ligands. Yayama et al. 21 have
shown the infiltration of several types of inflammatory cells including T cells and sterile pustules in PAO lesions. The pathogenesis of PAO is less well understood than that of PPP; however, tonsillar T cells may migrate into the affected joints and produce sterile pustules, as well as a PPP skin lesion. It is very interesting that quitting smoking after tonsillectomy was a predictive factor. It has been reported that smokers have a 74-fold higher risk for PPP, compared with non-smokers, and that skin lesions are more severe in smoking patients with PPP than in non-smoking patients. 22 We also showed that PPPASI was significantly higher in smoking patients than that in nonsmoking patients. The cessation of smoking has been shown to improve PPP skin lesions in a previous report. 23 Therefore, the effect of quitting smoking that we noted might have occurred, regardless of tonsillectomy. However, anesthesiologists generally recommend that patients who are to undergo intratracheal intubation under general anesthesia stop smoking before the operation. The advent of surgery must be an alluring opportunity for patients to stop smoking. In fact, 27 (49%) out of 55 patients who smoked were able to stop smoking after tonsillectomy in this study. This smoking cessation rate is comparable with that of nicotine replacement therapy. 24 To increase the improvement rate of PPP skin lesions after tonsillectomy, clinicians should stress quitting smoking after tonsillectomy. The development of a method to establish a diagnosis of tonsil-related disease is much anticipated. However, we have not found any clinical parameters that are suitable for the diagnosis. Another potential diagnostic method is the use of the tonsillar provocation test, which Nosaka et al. 25 propounded in 1977. Changes in the body temperature, white blood cell count and erythrocyte sedimentation rate have been examined, based on the conventional criteria for the provocation tests. However, patients who have negative results on these tests, based on the criteria, often improve after tonsillectomy. 26 Moreover, Kataura et al. 27 showed that the tonsillar provocation test was positive in only 41.7% of patients with PPP. This percentage is substantially lower than that of the patients whose PPP skin lesions improved after tonsillectomy; therefore, the existing criteria may produce many false-negative results. Thus, the diagnostic utility of tonsillar provocation tests for PPP has not been fully established.
As a consequence, we have not introduced using the test diagnostically for patients with PPP. After all, there is no method of diagnosing tonsil-related disease. Because of the high efficacy of tonsillectomy in improving the skin lesions and arthralgia, clinicians should at least present tonsillectomy as a treatment option to PPP and PAO patients who do not show improvement with conventional treatment. In fact, we recommend tonsillectomy to most PPP patients who are referred by a dermatologist. In summary, we showed the great efficacy of tonsillectomy for improving PPP skin lesions and PAO-induced pain, based on subjective self-assessment and on an objective method (i.e. the PPPASI). Moreover, quitting smoking and the presence of PAO were the significant factors that indicated disappearance of a skin lesion and an improvement of 80% or more in the skin lesion, respectively. Otolaryngologists, dermatologists and other doctors should share these findings and provide the best treatment for a patient suffering from PPP and PAO.
